Skip to main content

The Regulation Atmosphere

The pharmaceutical industry is cautiously optimistic that the new Bush administration and Congress will continue efforts to streamline the drug discovery and approval process. But the federal regulatory and licensing landscape will also be shaped this year by patent reform and gene therapy issues. In addition, two major pieces of legislation--one affecting drug approval times and the other market exclusivity--will either be phased out or reauthorized in the coming 18 months. "We really c

Written byTed Agres
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00

The pharmaceutical industry is cautiously optimistic that the new Bush administration and Congress will continue efforts to streamline the drug discovery and approval process. But the federal regulatory and licensing landscape will also be shaped this year by patent reform and gene therapy issues. In addition, two major pieces of legislation--one affecting drug approval times and the other market exclusivity--will either be phased out or reauthorized in the coming 18 months.

"We really can't say much about where the [Food and Drug Administration] may be headed under the Bush administration" until a new commissioner is named, says Jeff Trewhitt, spokesperson for the Pharmaceutical Research and Manufacturers of America (PhRMA). But he believes the American public is "pretty comfortable" with current drug standards and procedures, and notes that the drug industry is not seeking major changes to the process. The industry is heartened by the Republican National Committee's party platform, which ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo
Optimizing Critical Steps in T-Cell Engineering

Optimizing Critical Steps in T-Cell Engineering

Fujifilm

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen